Panel Discussion: Beyond the needle: Innovations in painless drug delivery
Drug delivery is undergoing a transformation driven by the demand for patient-friendly, painfree alternatives. As pharma R&D…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Intas Pharmaceuticals
Panel Discussion: Next-gen Pharma Innovation
The first panel discussion at Ahmedabad Pharma Summit 2025 was on ‘Next-gen Pharma Innovation.’ The session delved into the…
Pharma and healthcare deals in Q1 2025 remain stable amid shift to scalable global models
Grant Thornton Bharat reports 71 transactions totalling USD 2.6 billion in Q1 2025, with investor activity focused on mid-market…
Deal value declined by 86.4 per cent in Dec 2024, compared to Dec 2023
Three major deals contributed 70 per cent of the total deal value during December 2024
Accord BioPharma’s Biosimilar IMULDOSA gains USFDA approval for treatment of chronic inflammatory…
Intas Pharmaceuticals acquired exclusive commercialisation rights to DMB-3115 through a license agreement in 2021
Intas Pharma signs licensing pact with mAbxience for etanercept biosimilar
Intas gains exclusive commercialisation rights for Etanercept biosimilar for more than 150 countries worldwide
Intas Pharma and Comera Life Sciences enter into a research partnership
The companies will collaborate to develop bio-innovative biologic medicines
Intas launches Oral Azacitidine for adult patients with Acute Myeloid Leukaemia
With this, it becomes the first company to do so
UK fines pharma companies $360 million for overcharging NHS
The watchdog said the firms charged the NHS "excessively high prices" for almost a decade for the steroid hydrocortison
NPPA fixes retail prices of 30 formulations, rejects four applications
Two applications each of Micro Laboratories and Sun Pharma have been deferred by the authority